Publication

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH

BMC Gastroenterology 19(1):228, 2019

Kristiansen MB, Veidal SS, Christoffersen C, Feigh M, Hansen HH, Vrang N, Roth JD, Erickson M, Young M, Adorini L, Jelsing J

Subjects
Therapeutic AreaMouseTargetob/ob mouseCompoundMethod/EndpointSpeciesAMLN ob/ob-NASH (AMLN ob/ob-MASH) mouseBody weightNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)FXRElafibranorGLP-1 receptorImage analysisImmunohistochemistryLiver biopsyLiver morphometryPPARINT-767LiraglutideStereology

Share this page

Resource Library

Related resources
Poster
Development of hepatocellular carcinoma in the extended GAN diet-induced obese mouse model of NASH with advanced fibrosis
Poster
Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with diet-induced and biopsy-confirmed NASH
Poster
Preclinical efficacy and clinical translatability of lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH 
Publication
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top